Literature DB >> 24215617

Administrative coding is specific, but not sensitive, for identifying eosinophilic esophagitis.

D A Rybnicek1, K E Hathorn, E R Pfaff, W J Bulsiewicz, N J Shaheen, E S Dellon.   

Abstract

The use of administrative databases to conduct population-based studies of eosinophilic esophagitis (EoE) in the United States is limited because it is unknown whether the International Classification of Diseases, Ninth Revision (ICD-9) code for EoE, 530.13, accurately identifies those who truly have the disease. The aim of this retrospective study was to validate the ICD-9 code for identifying cases of EoE in administrative data. Confirmed cases of EoE as per consensus guidelines (symptoms of esophageal dysfunction and ≥15 eosinophils per high-power field on biopsy after 8 weeks of twice daily proton pump inhibitor therapy) were identified in the University of North Carolina (UNC) EoE Clinicopathologic Database from 2008 to 2010; 2008 was the first year in which the 530.13 code was approved. Using the Carolina Data Warehouse, the administrative database for patients seen in the UNC system, all diagnostic and procedure codes were obtained for these cases. Then, with the EoE cases as the reference standard, we re-queried the Carolina Data Warehouse over the same time frame for all patients seen in the system (n=308,372) and calculated the sensitivity and specificity of the ICD-9 code 530.13 as a case definition of EoE. To attempt to refine the case definition, we added procedural codes in an iterative fashion to optimize sensitivity and specificity, and restricted our analysis to privately insured patients. We also conducted a sensitivity analysis with 2011 data to identify trends in the operating parameters of the code. We identified 226 cases of EoE at UNC to serve as the reference standard. The ICD-9 code 530.13 yielded a sensitivity of 37% (83/226; 95% confidence interval: 31-43%) and specificity of 99% (308,111/308,146; 95% confidence interval: 98-100%). These operating parameters were not substantially altered if the case definition required a procedure code for endoscopy or if cases were limited to those with commercial insurance. However, in 2011, the sensitivity of the code had increased to 61%, while the specificity remained at 99%. The ICD-9 code for EoE, 530.13, had excellent specificity for identifying cases of EoE in administrative data, although this high specificity was achieved at an academic center. Additionally, the sensitivity of the code appears to be increasing over time, and the threshold at which it will stabilize is not known. While use of this administrative code will still miss a number of cases, those identified in this manner are highly likely to have the disease.
© 2013 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Keywords:  ICD-9 code; database; eosinophilic esophagitis; epidemiology; validation

Mesh:

Year:  2013        PMID: 24215617      PMCID: PMC4018425          DOI: 10.1111/dote.12141

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  38 in total

1.  Eosinophilic esophagitis.

Authors:  Richard J Noel; Philip E Putnam; Marc E Rothenberg
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

Review 2.  Eosinophilic esophagitis in adults: a systematic review.

Authors:  Spiros N Sgouros; Christina Bergele; Apostolos Mantides
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-02       Impact factor: 2.566

3.  Eosinophilic esophagitis: escalating epidemiology?

Authors:  Alex Straumann; Hans-Uwe Simon
Journal:  J Allergy Clin Immunol       Date:  2005-02       Impact factor: 10.793

4.  Prevalence of esophageal eosinophilia varies by climate zone in the United States.

Authors:  Jennifer M Hurrell; Robert M Genta; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2012-02-07       Impact factor: 10.864

5.  Markers of tyrosine kinase activity in eosinophilic esophagitis: a pilot study of the FIP1L1-PDGFRα fusion gene, pERK 1/2, and pSTAT5.

Authors:  E S Dellon; J J Bower; T O Keku; X Chen; C R Miller; J T Woosley; R C Orlando; N J Shaheen
Journal:  Dis Esophagus       Date:  2011-08-05       Impact factor: 3.429

6.  Association of eosinophilic inflammation with esophageal food impaction in adults.

Authors:  Tusar K Desai; Veslav Stecevic; Chung-Ho Chang; Neal S Goldstein; Kamran Badizadegan; Glenn T Furuta
Journal:  Gastrointest Endosc       Date:  2005-06       Impact factor: 9.427

7.  Fragility of the esophageal mucosa: a pathognomonic endoscopic sign of primary eosinophilic esophagitis?

Authors:  Alex Straumann; Livio Rossi; Hans-Uwe Simon; Pius Heer; Hans-Peter Spichtin; Christoph Beglinger
Journal:  Gastrointest Endosc       Date:  2003-03       Impact factor: 9.427

8.  Development and validation of a registry-based definition of eosinophilic esophagitis in Denmark.

Authors:  Evan S Dellon; Rune Erichsen; Lars Pedersen; Nicholas J Shaheen; John A Baron; Henrik T Sørensen; Mogens Vyberg
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

9.  Eosinophilic esophagitis: red on microscopy, white on endoscopy.

Authors:  Alex Straumann; Hans-Peter Spichtin; Kathleen A Bucher; Pius Heer; Hans-Uwe Simon
Journal:  Digestion       Date:  2004-09-20       Impact factor: 3.216

10.  Rapidly increasing incidence of eosinophilic esophagitis in a large cohort.

Authors:  B D van Rhijn; J Verheij; A J P M Smout; A J Bredenoord
Journal:  Neurogastroenterol Motil       Date:  2012-09-10       Impact factor: 3.598

View more
  12 in total

1.  Subcutaneous immunotherapy in patients with eosinophilic esophagitis.

Authors:  Benjamin S Robey; Swathi Eluri; Craig C Reed; Maya R Jerath; Michelle L Hernandez; Scott P Commins; Evan S Dellon
Journal:  Ann Allergy Asthma Immunol       Date:  2019-03-02       Impact factor: 6.347

2.  Eosinophilic Gastrointestinal Disorders Affect More Than Just the Esophagus.

Authors:  Nirmala Gonsalves; Glenn T Furuta; Dan Atkins
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-01       Impact factor: 2.839

3.  Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States.

Authors:  Elizabeth T Jensen; Michael D Kappelman; Christopher F Martin; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2014-09-30       Impact factor: 10.864

4.  Enrollment factors and bias of disease prevalence estimates in administrative claims data.

Authors:  Elizabeth T Jensen; Suzanne F Cook; Jeffery K Allen; John Logie; Maurice Alan Brookhart; Michael D Kappelman; Evan S Dellon
Journal:  Ann Epidemiol       Date:  2015-03-21       Impact factor: 3.797

Review 5.  The Global Face of Eosinophilic Esophagitis: Advocacy and Research Groups.

Authors:  Christine James; Amal Assa'ad
Journal:  Clin Rev Allergy Immunol       Date:  2018-08       Impact factor: 8.667

6.  Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database.

Authors:  Elizabeth T Jensen; Christopher F Martin; Michael D Kappelman; Evan S Dellon
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-01       Impact factor: 2.839

7.  Epidemiology of eosinophilic esophagitis.

Authors:  Evan S Dellon
Journal:  Gastroenterol Clin North Am       Date:  2014-03-19       Impact factor: 3.806

8.  The 2010-2015 Prevalence of Eosinophilic Esophagitis in the USA: A Population-Based Study.

Authors:  Emad Mansoor; Gregory S Cooper
Journal:  Dig Dis Sci       Date:  2016-06-01       Impact factor: 3.199

9.  Prevalence of eosinophilic esophagitis in the United States.

Authors:  Evan S Dellon; Elizabeth T Jensen; Christopher F Martin; Nicholas J Shaheen; Michael D Kappelman
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-11       Impact factor: 11.382

10.  Risk of Autoimmunity in EoE and Families: A Population-Based Cohort Study.

Authors:  Kathryn Peterson; Rafael Firszt; John Fang; Jathine Wong; Ken R Smith; Kristina A Brady
Journal:  Am J Gastroenterol       Date:  2016-05-24       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.